- Previous Close
5.1250 - Open
5.1300 - Bid 4.8700 x 100
- Ask 4.9500 x 100
- Day's Range
4.8900 - 5.1600 - 52 Week Range
3.6600 - 8.9000 - Volume
408,653 - Avg. Volume
541,803 - Market Cap (intraday)
480.849M - Beta (5Y Monthly) 0.66
- PE Ratio (TTM)
-- - EPS (TTM)
-1.7100 - Earnings Date Nov 6, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
15.50
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
www.alector.comRecent News: ALEC
View More
Performance Overview: ALEC
Trailing total returns as of 11/14/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ALEC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ALEC
View MoreValuation Measures
Market Cap
501.41M
Enterprise Value
78.85M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
7.75
Price/Book (mrq)
4.22
Enterprise Value/Revenue
1.28
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-257.54%
Return on Assets (ttm)
-19.25%
Return on Equity (ttm)
-112.55%
Revenue (ttm)
61.51M
Net Income Avi to Common (ttm)
-158.41M
Diluted EPS (ttm)
-1.7100
Balance Sheet and Cash Flow
Total Cash (mrq)
457.2M
Total Debt/Equity (mrq)
29.12%
Levered Free Cash Flow (ttm)
-66.92M
Research Analysis: ALEC
View MoreCompany Insights: ALEC
ALEC does not have Company Insights